The epothilone dilemma

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9048-9050

  De Jonge, Maja ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 310705; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IXABEPILONE; PACLITAXEL; RICINOMACROGOL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ZK EPO;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG MECHANISM; EDITORIAL; FATIGUE; HUMAN; HYPERSENSITIVITY; MICROTUBULE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; VOMITING; NEOPLASM; NOTE;

CLINICAL TRIALS; EPOTHILONES; HUMANS; NEOPLASMS;

EID: 33644820927     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.8844     Document Type: Editorial

References (29)

1. Goodin S, Kane MP, Ruben MH: Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22:2015-2025, 2004
2. Mani S, Macapinlac M Jr, Goel S, et al: The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 15:553-558, 2004
3. Østerlind K, Sánchez JM, Zatloukal P, et al: Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer. J Clin Oncol 23:647, 2005 (abstr 7110, suppl)
4. Melichar B, Tabernero J, Casado E, et al: Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC). J Clin Oncol 23:292, 2005 (abstr 3688, suppl)
5. Smit WM, SufliarskyJ, Spanik S, et al: Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. J Clin Oncol 23:468, 2005 (abstr 5056, suppl)
6. Rubin EH, Rothermel J, Tesfaye F, et al: Phase I, dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 23:9120-9129, 2005
7. Mani S, McDaid H, Hamilton A, et al: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 10:1289-1298, 2004
8. Hao D, Hammond LA, deBono JS, et al: Continuous weekly administration of the epothilone-B derivative, BMS247550 (NSC710428): A phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 21:103a, 2002 (abstr 411)
9. Eng C, Kindler HL, Nattam S, et al: A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 15:928-932, 2004
10. Galsky MD, Small EJ, Oh WK, et al: Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446, 2005
11. Okuno S, Maples WJ, Mahoney MR, et al: Evaluation of epothilone B analog in advanced soft tissue sarcoma: A phase II study of the phase II consortium. J Clin Oncol 23:3069-3073, 2005
12. ten Tije AJ, Verweij J, Loos W, et al: Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 42:665-685, 2003
13. Abraham J, Agrawal M, Bakke S, et al: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21:1866-1873, 2003
14. Zhuang SH, Agrawal M, Edgerly M, et al: A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 103:1932-1938, 2005
15. Yee L, Lynch T, Villalona-Calero M, et al: A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J Clin Oncol 23:652, 2005 (abstr 7127, suppl)
16. Piro LD, Rosen LS, Parson M, et al: KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 22:135, 2003 (abstr 539)
17. Mekhail T, Chung C, Holden S, et al: Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol 22:129, 2003 (abstr 515)
18. Sessa C, Perotti A, Malossi A, et al: Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc Am Soc Clin Oncol 22:130, 2003 (abstr 519)
19. Schmid P, Kiewe P, Kuehnhardt D, et al: A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. J Clin Oncol 23:147, 2005 (abstr 2051, suppl)
20. Baker SD, Verweij J, Rowinsky EK, et al: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94:1883-1888, 2002
21. Hussain A, Dipaola RS, Baron AD, et al: A phase IIa trial of weekly EP0906 in patients with hormone-refractory prostate cancer (HPRC). J Clin Oncol 22:397s, 2004 (abstr 4563, suppl)
22. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
23. Ajani JA, Shah MA, Bokemeyer C, et al: Phase II study of the novel epothilone BMS-247550 in patients (pts) with metastatic gastric adenocarcinoma previously treated with a taxane. Proc Am Soc Clin Oncol 21:155a, 2002 (abstr 619)
24. Vansteenkiste JF, Breton JL, Sandler A, et al: A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 22:626, 2003 (abstr 2519)
25. Roche HH, Cure H, Bunnell C, et al: A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:18, 2003 (abstr 69)
26. Poplin E, Moore M, O'Dwyer P, et al: Safety and efficacy of EPO906 in patients with advanced colorectal cancer: A review of 2 phase II trials. Proc Am Soc Clin Oncol 22:283, 2003 (abstr 1135)
27. Thompson JA, Swerdloff J, Escudier B, et al: Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc Am Soc Clin Oncol 22:405, 2003 (abstr 1628)
28. Zhuang SH, Menefee M, Kotz H, et al: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol 22:394a, 2004 (abstr 4550, suppl)
29. Pavlick AC, Millward M, Farrel K, et al: A phase II study of epothilone B analog (EpoB)-BMS 2477550 (NSC#710428) in stage IV malignant melanoma (MM). J Clin Oncol 22:720s, 2004 (abstr 7542, suppl)